Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trifluoroacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 8/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 5/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL28399119 | 0.95 | TP53 (0.40) | TP53FAAHEPHX1FUCA1HDAC3 | |
| Trifluoroacetic Acid SCHEMBL28666896 | 0.93 | TP53 (0.38) | TP53FAAHEPHX1FUCA1HDAC3 | |
| Trifluoroacetic Acid SCHEMBL28395953 | 0.91 | FAAH (0.50) | FAAHEPHX1FUCA1CES1CES2 | |
| Trifluoroacetic Acid SCHEMBL5494836 | 0.87 | FAAH (0.47) | FAAHEPHX1FUCA1CES1CES2 | |
| Trifluoroacetic Acid SCHEMBL28925949 | 0.87 | FUCA1 (0.33) | TP53FUCA1HDAC3HDAC1HDAC2 | |
| Trifluoroacetic Acid SCHEMBL3651032 | 0.85 | FFAR3 (0.35) | EPHX1FUCA1HDAC3HDAC1HDAC2 | |
| Trifluoroacetic Acid SCHEMBL15066947 | 0.83 | CA2 (0.39) | FAAHEPHX1FUCA1HDAC1CES1 | |
| Trifluoroacetic Acid SCHEMBL5238463 | 0.83 | FAAH (0.44) | FAAHEPHX1CES1CES2MEN1 | |
| Trifluoroacetic Acid SCHEMBL31031817 | 0.82 | FAAH (0.42) | FAAHEPHX1CES1CES2MEN1 | |
| Trifluoroacetic Acid SCHEMBL27841664 | 0.82 | FAAH (0.42) | FAAHEPHX1CES1CES2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805289-B | Preparation method of 1, 4-oxathia-3, 5-dialdehyde cyclohexadiene compound | 昆明理工大学 | 2024-05-28 | — | — | CN | claimed |
| US-11851392-B2 | Self-condensation of aldehydes | EASTMAN CHEMICAL COMPANY (US) | 2023-12-26 | — | — | US | claimed |
| CN-116082203-A | Shulin acid intermediate impurity and preparation method thereof | 宁波大红鹰药业股份有限公司 | 2023-05-09 | — | — | CN | claimed |
| CN-114805289-A | Preparation method of 1, 4-oxathia-3, 5-dialdehyde cyclohexadiene compound | 昆明理工大学 | 2022-07-29 | — | — | CN | claimed |
| EP-3880640-A1 | SELF-CONDENSATION OF ALDEHYDES | Eastman Chemical Company (US) | 2021-09-22 | — | — | EP | claimed |
| CN-112955423-A | Self-condensation of aldehydes | 伊士曼化工公司 | 2021-06-11 | — | — | CN | claimed |
| WO-2020101902-A1 | SELF-CONDENSATION OF ALDEHYDES | EASTMAN CHEMICAL COMPANY (US) | 2020-05-22 | — | — | WO | claimed |
| EP-1891019-A2 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Aventis Pharmaceuticals Inc. (US) | 2008-02-27 | — | — | EP | claimed |
| WO-2006044732-A2 | 2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-27 | — | — | WO | claimed |
| CN-114805289-B | Preparation method of 1, 4-oxathia-3, 5-dialdehyde cyclohexadiene compound | 昆明理工大学 | 2024-05-28 | — | — | CN | disclosed |
| US-20240109936-A1 | NOVEL MACROCYCLIC OPIOID PEPTIDES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| US-11851392-B2 | Self-condensation of aldehydes | EASTMAN CHEMICAL COMPANY (US) | 2023-12-26 | — | — | US | disclosed |
| CN-116082203-A | Shulin acid intermediate impurity and preparation method thereof | 宁波大红鹰药业股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-113336654-B | Preparation method of N-methyl-3- (2-methylphenoxy) amphetamine | 上海医药工业研究院 | 2022-12-09 | — | — | CN | disclosed |
| EP-1073658-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| US-6020450-A | Room temperature curable fluoropolymer composition; and fluorine-containing organosilicon compounds, a method of producing the same, and room temperature curable silicone composition containing the same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2000-02-01 | — | — | US | disclosed |
| WO-1999054333-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 1999-10-28 | — | — | WO | disclosed |
| US-5919886-A | FLUORINATED POLYAMIDESILICONES | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1999-07-06 | — | — | US | disclosed |
| US-5705591-A | Room temperature curable fluoropolymer composition; and fluorine-containing organosilicon compounds, a method of producing the same, and room temperature curable silicone composition containing the same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1998-01-06 | — | — | US | disclosed |
| EP-0745604-A2 | Room temperature curable fluoropolymer composition; and fluorine-containing organosilicon compounds, a method of producing the same, and room temperature curable silicone composition containing the same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1996-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851392-B2 | Self-condensation of aldehydes | ALKBH2, DBF4, ALKBH3 | TP53 2059/4885FAAH 1863/4885EPHX1 869/4885 |
| US-20240109936-A1 | NOVEL MACROCYCLIC OPIOID PEPTIDES | OPRL1, OPRM1, OPRK1 | TP53 4767/4885FAAH 1054/4885EPHX1 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.